Mustang Bio (MBIO) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.

Do analysts rate CASI or MBIO?

CASI Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 123.46%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Mustang Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more risk & volatility, CASI or MBIO?

CASI Pharmaceuticals has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.

Is CASI or MBIO more profitable?

Mustang Bio has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. Mustang Bio's return on equity of 0.00% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
Mustang Bio	N/A	N/A	-172.89%

Does the MarketBeat Community prefer CASI or MBIO?

CASI Pharmaceuticals received 33 more outperform votes than Mustang Bio when rated by MarketBeat users. However, 64.02% of users gave Mustang Bio an outperform vote while only 48.56% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 202 48.56%	Underperform Votes 214 51.44%
Mustang Bio	Outperform Votes 169 64.02%	Underperform Votes 95 35.98%

Which has stronger valuation and earnings, CASI or MBIO?

CASI Pharmaceuticals has higher revenue and earnings than Mustang Bio. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$31.37M	0.70	-$26.94M	-$2.55	-0.70
Mustang Bio	N/A	N/A	-$51.60M	-$78.00	-0.02

Does the media favor CASI or MBIO?

In the previous week, Mustang Bio had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Mustang Bio and 1 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 1.89 beat Mustang Bio's score of 0.43 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CASI Pharmaceuticals	Very Positive
Mustang Bio	Neutral

Do insiders and institutionals hold more shares of CASI or MBIO?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.9% of Mustang Bio shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CASI Pharmaceuticals beats Mustang Bio on 11 of the 17 factors compared between the two stocks.